503A vs. 503B: Why Outsourcing Facilities Are Held to Drug Manufacturer Standards

As an Industrial Pharmacist and long-time consultant in the manufacturing bio-pharmaceutical space, I’ve been following the growing trend of compounding pharmacies in the USA. It is now more common to find Warning Letters issued to compounding pharmacies, due to more scrutiny from the FDA.  Let’s try to understand what the difference and what prompts a pharmacy to fall into a difficult compliance situation that may jeopardize not only the safety of its patients, but the exposure to federal enforcement consequences.

Area	503A Pharmacy	503B Outsourcing Facility
Regulatory framework	FD&C Act §503A	FD&C Act §503B
FDA registration	Not registered as a 503B outsourcing facility	Must voluntarily register with FDA as an outsourcing facility
Primary oversight	State Board of Pharmacy; FDA may conduct surveillance/ for-cause inspections	Primarily FDA
Sterile compounding	May compound sterile preparations	Must compound sterile drugs to qualify as a 503B outsourcing facility
Patient-specific prescription	Generally required for an identified patient	Not required; may compound for office stock/healthcare-provider orders
CGMP	503A-compliant compounding is exempt from FDA CGMP requirements	FDA CGMP requirements apply
FDA premarket approval	Exempt if all 503A conditions are met	Exempt if all 503B conditions are met
Distribution	Primarily tied to dispensing to patients under pharmacy model	Can distribute to healthcare facilities/providers without patient-specific prescriptions
FDA adverse-event reporting	No equivalent 503B requirement	Required
FDA product reporting	No 503B periodic product reporting	Required, including semiannual product reporting
FDA inspections	Generally state-led, with FDA surveillance/for-cause authority	FDA risk-based inspections
Quality-system expectations	Pharmacy-compounding model	Drug-manufacturing/CGMP model

FDA specifically states that 503A compounders are exempt from CGMP when all conditions of §503A are satisfied, whereas 503B outsourcing facilities are subject to CGMP compliance under the 21CFR. 

The easiest way to identify them is:

503A = Pharmacy + Patient

503B = Outsourcing Facility + Manufacturing/Distribution

A 503A pharmacy generally compounds because a particular patient needs a compounded medication, like any registered retail pharmacy. A 503B outsourcing facility is designed more like a small-scale drug manufacturing operation, producing compounded drugs that can be distributed to healthcare providers without first receiving a prescription for an identified patient. 

USP vs. FDA: this is where it gets important

There is a common misconception that “USP is for 503A and FDA/CGMP is for 503B.” It is more nuanced.

503A:

For a 503A pharmacy, USP compounding chapters are extremely important, particularly:

• USP <795> — Pharmaceutical Compounding—Nonsterile Preparations 

• USP <797> — Pharmaceutical Compounding—Sterile Preparations 

• USP <800> — Hazardous Drugs—Handling in Healthcare Settings 

The applicable USP chapters establish standards for areas such as:

• personnel training 

• facilities 

• environmental controls 

• cleaning 

• equipment 

• compounding procedures 

• beyond-use dating 

• sterility assurance 

• quality control 

• documentation 

FDA's 503A framework also specifically incorporates USP/NF requirements for certain bulk drug substances. FDA states that a bulk substance used under 503A generally must comply with an applicable USP/NF monograph and the applicable USP compounding chapter, or satisfy the other statutory pathways for permitted bulk substances. 

Important: USP requirements do not replace the state pharmacy law. A 503A operation has to consider USP + state Board of Pharmacy requirements + applicable federal FDA requirements.

503B is different:

A 503B facility is subject to the FDA's current good manufacturing practice requirements under the FD&C Act. FDA inspects these facilities based on a risk-based approach, as any big or small pharmaceutical manufacturing company does.  That means you should evaluate a 503B much more like a drug manufacturer.

To comply and be inspection ready, any 503B should assess the following:

Quality System	Manufacturing	Laboratory/Testing
• Quality Unit independence  • deviations  • CAPA  • change control  • investigations  • complaints  • recalls  • supplier qualification • annual product/ process review considerations	• master batch records  • batch records  • process controls  • in-process controls  • yield/ reconciliation  • equipment qualification  • process validation where applicable	• specifications • analytical testing • sterility • endotoxin • potency/assay • identity • stability • microbiological controls

Facilities	Data Integrity	FDA Regulatory
• classified areas • environmental monitoring • HVAC • personnel/ material flows • cleaning/ disinfection • aseptic processing controls • contamination controls	• electronic systems • audit trails • access controls • electronic signatures • laboratory data • contemporaneous /attributable records	• FDA registration • product reporting • adverse-event reporting • FDA inspections • recalls • applicable registration requirements

FDA makes clear that simply registering as a 503B does not mean FDA has determined that the facility is CGMP compliant. Any 503B pharmacy must be ready to receive an FDA inspector at any time, announced or unannounced and face it based on the FDA Quality Systems Inspection Based Approach.

Regarding drug substances, “USP grade,” “pharmaceutical grade,” or having a COA does not by itself establish that a bulk substance is legally permissible for compounding under §503A or §503B.

In summary, 503A is fundamentally a patient-specific pharmacy-compounding model governed heavily by USP/state pharmacy requirements, while 503B is an FDA-regulated outsourcing-facility model subject to good manufacturing practices (cGMPs) and capable of producing compounded drugs for broader healthcare-provider distribution, thus subject to FDA scrutiny, inspection and enforcement as applicable by the law.

ProQuality helps compounding pharmacies by conducting assessments to address where the gaps might be and help mitigate them before falling victim of enforcement actions by the regulators.